<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724919</url>
  </required_header>
  <id_info>
    <org_study_id>0910X-101440</org_study_id>
    <nct_id>NCT00724919</nct_id>
  </id_info>
  <brief_title>A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli</brief_title>
  <official_title>Association of Antibiotic Utilization Measures and Control of Extended-Spectrum Î²-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post-
      intervention in the selected medical centres
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is post-interventional study to follow the acquisition rate of ESBP producing E. coli
      or K. pneumoniae at the sites involved in a previous interventional study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase</measure>
    <time_frame>48hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase</measure>
    <time_frame>48hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">256</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitted to ICU/burn unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion

          1. All patients admitted or transferred to ICU/burn unit.

          2. Patients of either sex, 18 years of age or older. Exclusion

        Patients were excluded if they had underlying conditions or diseases that were ultimately
        fatal within 48 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miaoli County</city>
        <zip>351</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <lastchanged_date>August 7, 2008</lastchanged_date>
  <firstreceived_date>July 23, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>ESBL</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
